News round-up for 11-15 March by DDW Digital Content Editor Diana Spencer.

Following the recent AD/PD 2024 conference, which took place on 5-9 March in Lisbon, Portugal, there have been a number of key announcements regarding investigational therapies for neurological disorders, particularly Alzheimer’s disease and Parkinson’s disease.

The top stories:

New drug shows promising neuroprotective effects

Galimedix Therapeutics has announced data showing small molecule GAL-201 has neuroprotective and symptomatic alleviation potential in models of Alzheimer’s disease (AD).

Preclinical studies demonstrate potential of zelquistinel in autism

Robust efficacy in several preclinical models supports high translational potential of zelquistinel in autism and reflects broader opportunity across synaptic dysfunction disorders.

NeuroSense reports positive results from its ALS trial

NeuroSense Therapeutics has reported additional positive data from its six-month double-blind Phase IIb PARADIGM trial of its lead drug candidate PrimeC for the treatment of amyotrophic lateral sclerosis (ALS).

£25.2 million raised to progress Parkinson’s treatment

Mission Therapeutics has raised £25.2 ($32.1) million to accelerate development of its lead drug candidates in the area of mitophagy, MTX325 and MTX652, through clinical trials.

Early trial data supports neurodegenerative disease-modifying drug

Biotechnology company Allyx Therapeutics has reported positive Phase 1b clinical data for its lead compound, ALX-001, a first-in-class, synapse-targeted, disease-modifying oral therapy in development for neurodegenerative diseases.